BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

Top 26 Companies Leading Sustainable Biopharma Practices in 2026

Sustainability has stopped being a side conversation in the pharmaceutical industry. In 2026 it sits at the centre of how the sector defines leadership. Th...

July 22, 2026 | Analysis

The Bioreactors Are Ours. The Consumables Are Not.

A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...

July 22, 2026 | Analysis

Rege Nephro Raises $10.6M to Advance iPS Cell-Based Kidney Disease Pipeline

inancing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline Rege Nephro Co., Ltd. ("Rege Nephr...

July 22, 2026 | News

Dimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipeline

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New D...

July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 16, 2026 | News

The Technology Is Ready. Are APAC’s Regulators?

In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...

July 15, 2026 | Regulatory

Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline o...

July 15, 2026 | News

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 14, 2026 | Analysis

The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.

A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...

July 13, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Stay Connected